期刊文献+

癌痛动物模型及病理机制研究进展 被引量:9

Research Progress on Animal Model and Pathological Mechanisms of Cancer Pain
下载PDF
导出
摘要 近年来不断出现的癌痛动物模型为癌症机制的研究提供了有效的工具。癌痛有其独特的病理机制,与外周敏化、中枢敏化、骨溶解和肿瘤对外周神经的直接作用等有关。全文综述癌痛动物模型及癌痛机制的研究进展。
机构地区 浙江中医药大学
出处 《中国肿瘤》 CAS 2007年第5期338-339,共2页 China Cancer
基金 国家"九五"攻关项目(96-906-10-01(02))
  • 相关文献

参考文献16

  • 1Schwei MJ,Honore P,Rogers SD,et al.Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain[J].J Neurosci,1999,19 (24):10886-10897.
  • 2Wacnik PW,Eikmeier LJ,Ruggles TR,et al.Functional interactions between tumor and peripheral nerve:morphology,algogen identification,and behavioral characterization of a new murine model of cancer pain[J].J Neurosci,2001,21 (23):9355-9366.
  • 3Wacnik PW,Kehl LJ,Trempe TM,et al.Tumor implantation in mouse humerus evokes movement-related hyperalgesia exceeding that evoked by intramuscular carrageenan[J].Pain,2003,101(1-2):175-186.
  • 4Medhurst SJ,Walker K,Bowes M,et al.A rat model of bone cancer pain[J].Pain,2002,96 (1-2):129-140.
  • 5Wang LX,Wang ZJ.Animal and cellular models of chronic pain[J].Adv Drug Deliv Rev,2003,55(8):949-965.
  • 6谭煌英,于莉莉,高福云,崔建,潘琳,田鑫,程志强,贾立群,李佩文.大鼠骨癌痛模型的建立及组织学研究[J].癌症进展,2005,3(1):75-79. 被引量:17
  • 7董航,田玉科,项红兵,田学愎.大鼠胫骨癌痛模型的制备及评价[J].中国临床康复,2006,10(20):77-79. 被引量:12
  • 8Nelson JB,Carducci MA.The role of endothelin-1 and endothelin receptor antagonists in prostate cancer[J].BJU Int,2000,85(Suppl 2):45-48.
  • 9Pomonis JD,Rogers SD,Peters CM,et al.Expression and localization of endothelin receptors:implications for the involvement of peripheral glia in nociception[J].J Neurosci,2001,21(3):999-1006.
  • 10张瑛,韩济生,王韵.癌症痛的神经生物学机制研究进展[J].生理科学进展,2004,35(3):224-228. 被引量:31

二级参考文献107

  • 1张瑛,韩济生,王韵.癌症痛的神经生物学机制研究进展[J].生理科学进展,2004,35(3):224-228. 被引量:31
  • 2项红兵,杨辉,安珂,田玉科.骨癌痛模型和相关疼痛病理机制研究进展[J].临床麻醉学杂志,2005,21(5):350-352. 被引量:15
  • 3[1]William J, Boyle W, Scott S, et al. Osteoclast differentiation and activation. Nature, 2003, 423:337-342.
  • 4[2]Lee ZH, Kim HH, Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Conunun, 2003,305:211-214.
  • 5[3]Novack DV, Yin L, Hagen-Stapleton A, et al. The I{kappa}B Function of NF-{ kappa } B2 p100 controls stimulated osteoclastogenesis. J Exp Med, 2003, 198:771-781.
  • 6[4]Mansky KC, Sankar U, Han J, et al. Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling. J Biol Chem, 2002,277: 11077-11083.
  • 7[5]Hotokezaka H, Sakai E, Kanaoka K, et al. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem, 2002,277:47366-47372.
  • 8[6]Miyazaki T, Katagiri H, Knnegae Y, et al. Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol,2000,148 : 333-342.
  • 9[7]Ha H, Kwak HB, Lee SK, et al. Membrane rafts play a crucial role in receptor activator of nuclear factor kappaB signaling and osteoclast function. J Biol Chem, 2003,278: 18573-18580.
  • 10[8]Mandine E, Jean-Baptiste V, Vayssiere B, et al. High-affinity Src-SH2 ligands which do not activate Tyr(527)-phosphorylated Src in an experimental in vivo system. Biochem Biophys Res Conunun, 2002,298: 185-192.

共引文献81

同被引文献123

引证文献9

二级引证文献147

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部